Solid revenue growth

During the Period, the Company expects to record operating revenue of approximately RMB3.2 billion to RMB4.0 billion, representing an estimated increase of about 22% to 52% compared with the same period in 2025. In addition, profit attributable to owners of the Company is expected to be in the range of approximately RMB90 million to RMB130 million, representing a marked improvement compared with the loss recorded in the corresponding period of 2025.

Growth drivers

The strong revenue growth has mainly been driven by the continued upgrade of the shared technology platform underpinning Phancy’s various business lines. The enhanced platform capabilities have attracted more enterprise customers and stimulated demand. At the same time, the throughput efficiency of the Company’s self-owned and leased computing power resource tokens has increased significantly, accelerating the release of token productivity and in turn supporting faster growth in operating revenue.

The expected turnaround in profit attributable to owners of the Company from loss to profit has primarily been attributable to three factors:

• rapid growth of the Company’s principal businesses;
• a substantial improvement in sales expenses as a percentage of revenue compared with the same period last year, resulting in a healthier cost structure; and
• a sharp year-on-year increase in net other income and gains, mainly due to an increase in the fair value of the Company’s investment projects.

Phancy expects to announce its interim results for the six months ended 30 June 2026 by the end of August 2026. The Company will continue to pursue technological innovation and open collaboration, further enhance its full-stack AI cloud platform, and advance its “Token Factory” into more industry scenarios to unlock new-quality productivity.

Hashtag: #Phancy

The issuer is solely responsible for the content of this announcement.

Through DaaS, enterprise customers can access drone equipment, trained personnel, mission execution, data collection and project deliverables without purchasing and maintaining a complete in-house drone system. The model extends ZenaTech’s business beyond equipment sales and enables the company to generate recurring service revenue from customers’ operational requirements.

ZenaTech reported revenue of CAD 8.4 million for the first quarter of 2026, an increase of 640% from CAD 1.13 million in the same period of 2025. DaaS contributed approximately CAD 7.8 million, accounting for around 93% of quarterly revenue.

In 2025, the company generated annual revenue of CAD 12.9 million, up 558% from approximately CAD 2 million in 2024. DaaS contributed approximately CAD 10.1 million during its first full year of operations, representing around 78% of total annual revenue.

Acquisitions Support Service Network Expansion

ZenaTech has expanded its DaaS operations through a combination of internal technology development and acquisitions. The acquired businesses bring existing customers, professional teams and local operating capabilities, while ZenaTech gradually introduces drones, automated data collection and AI-supported analytics into selected workflows.

In 2025, the company completed 20 acquisitions, including 19 businesses providing engineering data, facility inspection and related professional services, as well as one enterprise software company.

By June 2026, ZenaTech had completed its 24th DaaS-related acquisition and expanded its services into property cleaning, facility inspection and maintenance.

Through its ZenaDrone subsidiary, ZenaTech has also developed drone products for indoor and outdoor operations. The IQ Quad supports site data collection, engineering imagery and 3D modelling, while the IQ Nano uses barcode and RFID scanning to support inventory records, shelf inspections and indoor data collection.

The company’s reported revenue growth, acquisition activity and DaaS contribution provide investors following the AI and drone sectors with measurable indicators of how its technologies are being integrated into commercial operations and converted into service revenue.

Hashtag: #ZenaTech

The issuer is solely responsible for the content of this announcement.

About ZenaTech

ZenaTech (Nasdaq: ZENA) is a technology company specialising in AI-powered drones, Drone-as-a-Service (DaaS), enterprise SaaS solutions and related technologies. Through its ZenaDrone subsidiary, the company develops drone products and software for commercial applications including engineering data collection, agriculture, warehouse management, facility inspection and property maintenance. ZenaTech combines its technology capabilities with a growing professional service network to support the adoption of drone-based solutions across a range of operational environments.

The proposed indications for use describe SPOT-MAS 10 as a qualitative in vitro diagnostic test performed on plasma derived from a single direct-draw venous whole blood specimen. The test analyzes circulating cell-free DNA methylation and fragmentomic signatures using a machine-learning-based algorithm to detect a cancer-associated signal. It is intended for use as an adjunctive screening test in asymptomatic adults aged 40 years and older to assist in detecting cancers within the scope of the assay. These include five common cancers — breast, lung, liver, colorectal and gastric cancers — and five aggressive, less common cancers that currently lack standard screening methods — ovarian, pancreatic, esophageal, endometrial and head & neck cancers.

SPOT-MAS has been developed through years of rigorous scientific research and clinical development. In March 2025, SPOT-MAS became the first multi-cancer screening blood test in Asia to complete a large prospective cohort validation, with the K-DETEK study evaluating more than 9,000 asymptomatic participants and demonstrating strong performance, including high specificity and the ability to identify cancer-associated signals across multiple cancer types.

Since then, SPOT-MAS has been used in more than 100,000 individuals in real-world practice, with consistent performance observed beyond controlled study settings. Real-world data were presented at ESMO Asia 2025 and were featured at ASCO Breakthrough 2026 in Singapore.

The platform is built on a multi-omic approach— integrating genetics, epigenetics, and fragmentomics — together with AI-driven analysis, large-scale prospective validation, growing real-world evidence and focus on cancer types with high clinical relevance in the regions where the test is deployed.

For the United States, Breakthrough Device Designation provides Gene Solutions with a prioritized channel of engagement with the FDA as the company advances its U.S. development and validation plans.

Looking ahead, Gene Solutions will continue to collaborate with academic, clinical, laboratory, commercial and strategic partners to support responsible adoption of SPOT-MAS in accordance with local regulations, clinical guidelines and best practices.

Important Regulatory Notice: SPOT-MAS 10 has received U.S. FDA Breakthrough Device Designation. Breakthrough Device Designation is not FDA approval, clearance or marketing authorization. The device remains subject to applicable FDA regulatory review requirements, and the designation does not guarantee future FDA approval, clearance or authorization.

For more information, visit https://spotmas.com.hk

Contact:
hk***@***********ns.com
Source: Gene Solutions Hong Kong Limited.
SPOTMAS_062026_04

Hashtag: #SPOTMAS

https://spotmas.com.hk/

The issuer is solely responsible for the content of this announcement.